The vexations of Vioxx

Sibbald, Barbara
February 2006
CMAJ: Canadian Medical Association Journal;2/14/2006, Vol. 174 Issue 4, p444
Academic Journal
The article reports on the error committed by the "New England Journal of Medicine" regarding the publication of a study on the drug, rofecoxib, in 2000. The study was published despite incomplete adverse event information. Meanwhile, Merck & Co., the manufacturer of Vioxx-branded rofecoxib, faced lawsuits due to harmful side effects of the drug. The drug could cause myocardial infarction, heart attack and stroke. INSET: Vioxx timeline.


Related Articles

  • Drug-induced disorders. Holland, Eileen C.; Degruy, Frank V. // American Family Physician;11/1/1997, Vol. 56 Issue 7, p1781 

    Focuses on drug-induced disorders. Common-type of drug-induced disorders; Drug associated with drug-induced problems; Clinical manifestations of drug-induced disorders; Factors that contribute to the development of adverse drug reactions; How to recognize an adverse drug reaction.

  • PHARMACOTHERAPEUTICAL STUDY OF MYOCARDIAL INFARCTION. Ziauddin; Ali, N.; Sultan, U.; Haq, Z. // Canadian Journal of Applied Sciences;Mar2012, Vol. 2 Issue 1, p233 

    Myocardial Infarction arises due to disruption of balance between supply and demand of blood to the heart muscles, and is a leading cause of death all around the World. This study was conducted on patients data collected in "Cardiac Care Unit and Cardiology Ward" one of the leading hospital in...

  • Strattera: increased risk of suicidal ideation in children and adolescents.  // Reactions Weekly;10/8/2005, Issue 1072, p2 

    Reports on the announcement by Eli Lilly and Co. that the Strattera label for atomoxetine will be updated globally to warn of a possible association between the drug and suicidal ideation in children and adolescents in the U.S. Analysis of adverse events from Strattera clinical trials; Safety...

  • Carboplatin/cisplatin/etoposide.  // Reactions Weekly;9/16/2006, Issue 1119, p8 

    The article presents a case report of a male patient who developed chronic myelomonocytic leukemia after platinum-based antineoplastic therapy, based on a study by K. B. Kim, S. Faderl et al., published in the August 2006 issue of the "Journal of Clinical Pharmacy and Therapeutics." A brief...

  • Fluticasone propionate interaction.  // Reactions Weekly;1/6/2007, Issue 1133, p11 

    The article discusses research being done on various patients receiving ritonavir and lopinavir, who developed Cushing's syndrome during concomitant treatment with fluticasone propionate. It references a study by R. Arrington-Sanders and colleagues, published in the November 2006 issue of...

  • The Systems Biology Approach to Drug Development: Application to Toxicity Assessment of Cardiac Drugs. Rodriguez, B.; Burrage, K.; Gavaghan, D.; Grau, V.; Kohl, P.; Noble, D. // Clinical Pharmacology & Therapeutics;Jul2010, Vol. 88 Issue 1, p130 

    Side effects account for most of the instances of failure of candidate drugs at late stages of development. These development failures contribute to the exorbitant cost of bringing new compounds to market: a single withdrawal can represent a loss of more than $1 billion. Many unwanted actions of...

  • The declining prevalence of ST elevation myocardial infarction in patients presenting with acute coronary syndromes. Kleiman, N. S.; White, H. D. // Heart;Sep2005, Vol. 91 Issue 9, p1121 

    Focuses on the declining prevalence of ST elevation myocardial infarction in patients presenting with acute coronary syndromes (ACS). Side effects of drugs used for the treatment of heart diseases; Role of cigarette smoking in ST elevation; Information that hypertension is recognised as a risk...

  • A simple recipe for drug interaction networks earns its stars. Schmatz, Dennis; Friend, Stephen // Nature Genetics;Apr2006, Vol. 38 Issue 4, p405 

    A new study elucidates a drug interaction network using a simple combination of theory and experiments, testing drug combinations on Escherichia coli. The results are elegant, uncovering drug interactions shared within drug classes and providing useful tools for functional classifications of drugs.

  • Rosiglitazone risks questioned. Pedder, Cato // Pulse;6/14/2007, Vol. 67 Issue 23, p14 

    The article reports on the contradictory findings of two studies concerning the possible risks involved in the administration of the drug rosiglitazone in patients. A meta-analysis of 42 trials revealed that the drug increased the risk of heart attack among patients by 43 percent. On the other...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics